FDA Officials Say Potency Problems Main Reason for NTI Drug Recalls
This article was originally published in The Gold Sheet
Executive Summary
FDA officials said that use of quality by design as well as “equivalence by design” will help drug manufacturers develop better generic substitutions of narrow therapeutic index (NTI) drugs to address the high rate of recalls associated with these products due to potency problems.